Literature DB >> 8285546

Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis.

N D Barber1, U K Hoffmeyer.   

Abstract

The cost-effectiveness of subcutaneous heparin (20,000 iu, twice daily, prefilled syringes), a continuous intravenous infusion of 24,000 iu heparin in 24 h, and the intravenous infusion of 48,000 iu heparin as two consecutive 12-h infusions of 24,000 iu, were compared. The costs were calculated by timing and observing staff in three hospitals, and by noting the costs of what they used. Cannulation of a vein by a doctor took a mean of 4 min 16 s and cost 2.61 pounds. To prepare and administer the 24,000 iu of heparin in a 24-h infusion took a mean of 22 min 42 s/day and cost 9.52 pounds. If a 48,000 iu in 24-h infusion was used it took a mean of 36 min 3 s/day and cost 16.81 pounds. The use of heparin syringes, 20,000 iu subcutaneously twice daily, took 2 min 53 s/day and cost 4.80 pounds. A generic cost formula was calculated to allow for variation in staff or drug costs. The subcutaneous and intravenous routes were assumed to be equally effective on the basis of the medical literature. This study shows that subcutaneous heparin therapy is significantly more cost-effective than intravenous heparin therapy. The reduction in cost and liberation of nursing time mean that the subcutaneous route should be preferred.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8285546      PMCID: PMC2498021     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  3 in total

Review 1.  Overview of the management of thrombotic disorders.

Authors:  A S Gallus
Journal:  Semin Thromb Hemost       Date:  1989-04       Impact factor: 4.180

2.  Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.

Authors:  R D Hull; G E Raskob; D Rosenbloom; A A Panju; P Brill-Edwards; J S Ginsberg; J Hirsh; G J Martin; D Green
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

3.  Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis.

Authors:  D W Hommes; A Bura; L Mazzolai; H R Büller; J W ten Cate
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

  3 in total
  3 in total

Review 1.  Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.

Authors:  D Heaton; M Pearce
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

2.  Ready-to-use injection preparations versus conventional reconstituted admixtures: economic evaluation in a real-life setting.

Authors:  Phillipe van der Linden; Jacques Douchamps; Claude Schmitt; Dominique Forget
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Authors:  Jing-Fen Jin; Ling-Ling Zhu; Meng Chen; Hui-Min Xu; Hua-Fen Wang; Xiu-Qin Feng; Xiu-Ping Zhu; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.